Publication Year

Movva N, Reichert H, Hooda N, Bylsma LC, Mitchell M, Cohen SS. 2023. Dietary eating patterns, dairy consumption, and anxiety: A systematic literature review. PLoS One 18(12):e0295975. doi: 10.1371/journal.pone.0295975. PMID: 38153944.

Bylsma LC, Pundole X, Ju C-H, Hooda N, Movva N, Elkhouly E, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Target Oncol [open access].

Wikoff D, Ring C, DeVito M, Walker N, Birnbaum L, Haws L. 2023. Development and application of a systematic and quantitative weighting framework to evaluate the quality and relevance of relative potency estimates for dioxin-like compounds (DLCs) for human health risk assessment. Regul Toxicol Pharmacol 145:105500; doi: 10.1016/j.yrtph.2023.105500.

Perry CS, Blanchette AD, Vivanco SN, Verwiel AH, Proctor DM. 2023. Use of physiologically based pharmacokinetic modeling to support development of an acute (24-hour) health-based inhalation guideline for manganese. Regul Toxicol Pharmacol 145:105518.

Franklin M, Emden MR, Bauer E, Nguyen AT, Sacks N, Kawamatsu S, Kawano Y,  Mitrani-Gold FS, Joshi AV, Ju S, Preib MT. Prevalence of acute uncomplicated cystitis in Japan. Poster presentation, IDWeek, October 2023.

Franklin M, Emden MR, Kautz S, Nguyen AT, Sacks NC, Ju S, Mitrani-Gold FS, Joshi AV, Preib MT. Cost burden of patients with oral antibiotic treatment failure for uncomplicated urinary tract infection in the United States. Poster presentation, IDWeek, October 2023.

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145:105521; doi: 10.1016/j.yrtph.2023.105521.

Pastula S, Bylsma LC, Movva N, Rege S, Lewis RJ, Fryzek JP. 2023. Scoping review of indices to monitor community health. Open Science Framework.

Nelson CB, Jiang X, Suh M, Fryzek J. Prevention of respiratory syncytial virus hospitalizations (RSVH) in US infants who paid through Medicaid would have a greater benefit for Black, Hispanic, Asian/Pacific Islander, Native American and Other race/ethnicity infants, and have a substantial impact on overall RSVH burden and related costs: Rates of respiratory syncytial virus hospitalization (RSVH) among US infants by race/ethnicity and insurance payer, NIS 2018-2020. Poster 1536169, IDWeek 2023, Boston, MA, October 2023.

Blatt A, Suh M, Walter E, Jr., Wood CT, Espinosa C, Enriquez-Bruce ME…Movva N, Reichert H, Fryzek JP, et al. Seasonality of infant respiratory syncytial virus associated bronchiolitis around the US since the onset of COVID-19: Results from four US health systems 2016-17 through 2022-23. Poster 1535431, IDWeek 2023, Boston, MA, October 2023.